New Drugs Hailed as a 'Turning Point' in Treating Antibiotic-Resistant Gonorrhoea
The first new treatments for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against increasingly resistant strains of the bacteria, according to scientists.
A Global Health Concern
Gonorrhoea infections are escalating worldwide, with figures suggesting over 82 million new cases annually. Especially elevated rates are reported in the African continent and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.
“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the face of increasing worldwide cases, the spread of superbugs and the highly restricted therapeutic options currently available.”
Public health authorities are particularly alarmed about the increase in drug-resistant strains. The WHO has designated it as a "critical concern". A tracking program found that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.
A Pair of Novel Treatment Options Gain Clearance
Zoliflodacin, marketed under the name a brand name, was approved by the US FDA in December for treating gonorrhoea. This STI can lead to major issues, including infertility. Researchers hope that focused deployment of this new drug will help slow the emergence of superbugs.
Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This treatment, which is also used to treat UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.
A Novel Partnership
Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.
“This milestone represents a significant shift in the therapy of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”
Research Study Data and Worldwide Availability
As per results detailed in a major medical journal, the new drug successfully treated over nine in ten of cases of the STI. This places it at an comparable level with the typical regimen, which uses two antibiotics. The research enrolled hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.
As part of the agreement of its collaboration, GARDP has the ability to license and sell the drug in a wide range of regions with limited resources.
Clinicians directly involved have voiced optimism. Access to a easy-to-administer therapy such as this is hailed as a "game-changer" for managing the epidemic. This is considered crucial to reduce the burden of the disease for patients and to prevent the spread of untreatable gonorrhoea around the world.
